徐承义,苏晞,宋丹,彭剑,何蕾

• 1:武汉亚洲心脏病医院心内科

摘要(Abstract)：

目的观察冠状动脉慢性完全闭塞病变(CTO)经皮冠状动脉介入治疗(PCI)术后应用替格瑞洛治疗的有效性和安全性。方法回顾性分析武汉亚洲心脏病医院2012年10月至2013年9月216例行PCI成功的CTO患者的临床资料,术后给予替格瑞洛治疗作为研究组(82例),继续氯吡格雷治疗的患者为对照组(134例)。研究主要终点为两组患者随访1年的主要不良心血管事件(MACE,包括支架内急性或亚急性血栓形成、非致死性心肌梗死、靶血管再次血运重建、心原性死亡)的发生率;次要终点为一般不良事件(包括出血、呼吸困难)的发生率。结果随访12个月,两组患者总体MACE发生率比较,差异无统计学意义(15.6%比21.3%,P=0.318),但非致死性心肌梗死发生率在研究组显著降低(3.9%比12.6%,P=0.038)。两组患者出血事件发生率比较,差异无统计学意义(13.0%比9.4%,P=0.430),但研究组呼吸困难更为多见(9.1%比1.6%,P=0.011)。结论与氯吡格雷比较,替格瑞洛用于CTO-PCI术后临床疗效确切,且不增加出血风险,但呼吸困难症状较多见。

关键词(KeyWords)： 慢性完全闭塞病变;经皮冠状动脉介入治疗;氯吡格雷;替格瑞洛

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 徐承义,苏晞,宋丹,彭剑,何蕾

参考文献(References)：

• [1]King SB 3rd,Aversano T,Ballard WL,et al.ACCF/AHA/SCAI2007 Update of the clinical competence statement on cardiac interventional procedures:a report of the American College of Cardiology Foundation/American Heart Assocation/American College of Physicians Task Force on Clinical Competence and Training(writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures).J Am Coll Cardiol,2007,50:82-108.
• [2]Fefer P,Knudtson ML,Cheema AN,et al.Coronary perspectives on coronary chronic total occlusions.The canadian multicenter chronic total occlusions registry.J Am Coll Cardiol,2012,59:991-997.
• [3]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361:1045-1057.
• [4]James S,Akerblom A,Cannon CP,et al.Comparison of ticagrelor,the first reversible oral P2Y(12)receptor antagonist,with clopidogrel in patients with acute coronary syndromes:Rationale,design,and baseline characteristics of the PLATelet inhibition and patient Outcomes(PLATO)trial.Am Heart J,2009,157:599-605.
• [5]Mitsudo K,Yamashita T,Asakura Y,et al.Recanalization strategy for chronic total occlusions with tapered and stiff-tip guidewire.The results of CTO New technique for Standard procedure(CONQUEST)trial.J Invasive Cardiol,2008,20:571-577.
• [6]Fox KA,Mehta SR,Peters R,et al.Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome:the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events(CURE)Trial.Circulation,2004,110:1202-1208.
• [7]Montalescot G,Lassen JF,Hamm CW,et al.Ambulance or incatheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction:Rationale and design of the randomized,double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery(ATLANTIC)study.Am Heart J,2013,165:515-522.
• [8]Wartak SA,Lotfi A,Rothberg M.Ticagrelor versus clopidogrel in acute coronary syndromes.N Engl J Med,2009,361:2386-2387.
• [9]Storey RF,Becker RC,Harrington RA,et al.Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel(from the Platelet lnhibitien and Patient Outcomes[PLATO]Pulmonary Function Substudy).Am J Cardiol,2011,108:1542-1526.
• [10]Ohman J,Kudira R,Albinsson S,et al.Ticagrelor induces adenosine triphosphate release from human red blood cells.Biochem Biophys Res Commun,2012,418:754-758.
• [11]马颖艳,王艳霞,徐白鸽,等.替格瑞洛用于经皮冠状动脉介入治疗术后患者抗血小板治疗短期内的有效性和安全性研究.中国介入心脏病学杂志,2014,22:380-383.